Epidermolysis Bullosa Dystrophic
📧 Sign up to get email alerts when something new happens for Epidermolysis Bullosa Dystrophic.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Artificial Intelligence Patient App for RDEB SCCs
Clinical trial update indicates an Artificial Intelligence-based patient app for patients with epidermolysis bullosa dystrophica and related…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
A clinical trial update from Amryt Pharma about a study to assess the incidence of skin cancers in patients with epidermolysis bullosa recei…
-
EMA approval · 2025-07-11EMA Authorised: Filsuvez (dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w)) — Chiesi Farmaceutici S.p.A
EMA authorised Filsuvez for epidermolysis bullosa dystrophica and junctional forms; the marketing authorization holder is Chiesi Farmaceutic…
-
CLINICAL_TRIALS trial_result · 2010-06-22Clinical Trial Update: Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) [Phase 3]
Phase 3 trial evaluating Apligraf for nonhealing wounds in patients with epidermolysis bullosa (junctional or dystrophic) was terminated, wi…